Teleflex Convenes Urologists in Australia for Summit on Treating Benign Prostatic Hyperplasia and Lower Urinary Tract Symptom...
January 14 2020 - 6:30AM
Teleflex Incorporated (NYSE: TFX) recently hosted urologists from
around the world to review clinical data and share best practices
for using the UroLift® System to improve the care of patients with
an enlarged prostate, or benign prostatic hyperplasia (BPH).
Throughout the day-and-a-half Inaugural ANZ BPH Summit, held at
the Pullman Sydney Airport Hotel Nov. 15-16, attendees learned
about the advancement of BPH treatment and the evolution of the
UroLift System, reviewed clinical data, and exchanged best
practices, and advanced techniques for treating BPH.
“It was fantastic to have passionate international and local
urologists gather at the Inaugural ANZ BPH Summit to share their
experiences, knowledge, and advancements in BPH treatment,” said
Alistair McKeon, General Manager Teleflex Australia and New
Zealand. “We’re very fortunate to work with such a dedicated group
of physicians in shaping the future of minimally invasive BPH
treatment.”
“The UroLift System was developed as an innovative solution for
BPH that involves no cutting, heating or removal of tissue, in a
simple procedure,” added co-founder Ted Lamson.
BPH, also known as an enlarged prostate, is non-cancerous
enlargement of the prostate that occurs as men age. The condition
affects over 680,000 men in the Australia alone. More than 40% of
men in their 50s have BPH and over 80% of men in their 70s have
BPH. The symptoms of BPH can cause loss of productivity,
depression, and decreased quality of life.1 In addition, if left
untreated the condition can worsen over time and cause permanent
bladder damage.2
About the UroLift® SystemThe FDA-cleared
UroLift System is a proven, minimally invasive technology for
treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during
a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
an enlarged prostate receiving UroLift implants reported rapid and
durable symptomatic and urinary flow rate improvement without
compromising sexual function.*3,4 Patients also experienced
significant improvement in quality of life. Over 100,000 men have
been treated with the UroLift System worldwide. Most common adverse
events reported include hematuria, dysuria, micturition urgency,
pelvic pain, and urge incontinence. Most symptoms were mild to
moderate in severity and resolved within two to four weeks after
the procedure. The Prostatic Urethral Lift procedure using the
UroLift System is recommended for the treatment of BPH in both the
American Urological Association and European Association of Urology
clinical guidelines. The UroLift System is available in many
markets worldwide. Learn more at www.UroLift.com.
About Teleflex Interventional UrologyThe
Teleflex Interventional Urology Business Unit is dedicated to
developing innovative, minimally invasive and clinically effective
devices that address unmet needs in the field of urology. Our
initial focus is on improving the standard of care for patients
with BPH using the UroLift System, a minimally invasive permanent
implant system that treats symptoms while preserving sexual
function.*3,4 Learn more at www.NeoTract.com.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular and interventional access,
surgical, anesthesia, cardiac care, urology, emergency medicine and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
Contacts:
For Teleflex Incorporated:Jake Elguicze, 610.948.2836Treasurer
and Vice President, Investor Relations
Media:Nicole Osmer, 650.454.0504nicole@healthandcommerce.com
1 Speakman et al. 2014 BJU International2 Tubaro et al.
2003 Drugs Aging3 Roehrborn, J Urology 2013 LIFT Study4 Shore, Can
J Urol 2014 Local Study*No instances of new, sustained erectile or
ejaculatory dysfunction
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024